Want to minimize chance of contracting bird flu? Eat less chicken
I have been following closely our country's bird flu crisis and am especially concerned about the recent revelation that a new strain of the virus, H5N9, has been detected in California. This is the development many public health officials have been most concerned about as it indicates that bird flu is mutating in a way that could allow it to spread more easily to humans.
For this reason, I was shocked when I read the news that the new administration has halted the release of public health information related to the study of bird flu virus, including knowledge that could help reduce the risk of contagion. I call on Sens. Ossoff and Warnock and my Congressman Richard McCormick to do everything in their power to see that communication and information related to ameliorating our nation's bird flu virus epidemic is permitted.
The administration would do well to follow the lead of Georgia— often dubbed the poultry capital of the world—which is taking definitive action against the spread of bird flu. Georgia has suspended all poultry operations in an effort to control this outbreak. At least two commercial poultry operations in our state have been hit recently by H5N1. Healthcare professionals are monitoring this situation and remain hopeful that Georgia does not join the list of states in which human cases of bird flu have been detected.
I applaud our public health officials for doing what they can to keep the bird flu from spreading but the reality is that the virus has sickened dozens of people, decimated poultry populations, and infected dairy cows. Now is the time to take a hard look at the food production system that puts farm workers in close contact with sick birds and cows, the Standard American Diet that demands it, and the health ramifications of both.
From a doctor's perspective, shifting food production away from intensive animal agriculture can benefit public health. Facilities with large numbers of animals in a small amount of space are a concern for public health because they provide ideal conditions for viruses to spread, evolve, and possibly acquire the ability to more easily infect people. Intensive animal agriculture was implicated when influenza viruses H1N1, H5N1, and N7N9 jumped from animals to people, according to research published in Frontiers in Microbiology.
The life of a contract chicken grower can be challenging, and some of them are repurposing their chicken houses to grow crops. North Carolina poultry farmers Dale and Paula Boles switched from chickens, converted their 500-foot-long poultry barn to a greenhouse, and now grow organic vegetables. They are not alone. In Southwest Arkansas, farmers Jennifer and Rodney Barrett are transitioning from raising poultry and cattle to growing mushrooms.
These farm transitions aren't easy. The government should provide financial and technical support. Georgia could help its farmers with a program like the one established by lawmakers in Vermont who provide grants to farmers who wish to diversify or transition from one type of farming to another.
Georgia is full of opportunity for poultry and dairy farmers who want to transition to crops or orchards. Plant-based foods like beans and legumes grown in Georgia can help people improve heart health, prevent diabetes, and maintain a healthy weight, among other benefits. The Georgia peach is my favorite but cantaloupe, sweet corn, peanuts, blueberries, watermelons, and cucumbers are also healthful options that can provide income to Georgia farmers.
Shifting away from animal agriculture helps our environment and improves worker safety as well. Large-scale poultry operations produce huge amounts of waste and contribute to waterways overloaded with phosphorous, and other pollutants. Poultry farms are a primary source of water, air, and land pollution.
I have found for myself and my patients that removing animal products from the diet improves health, and the scientific literature tells the same story. A recent study with 22 pairs of identical twins found that a plant-based diet improves heart health in as little as eight weeks. The twins following a plant-based diet experienced lower LDL, or 'bad' cholesterol, and they lost more weight than the omnivore twins.
In the short term, let's allow our public health officials to communicate in order to stop the spread of this virus. Taking a long view, government grants and other assistance should be available if Georgia poultry farmers or egg producers would like to switch to growing crops and planting orchards, which will also benefit human health and the environment.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NBC News
3 days ago
- NBC News
Needle-phobic? FluMist nasal spray vaccine available for use at home
More children died from the flu this past season than any year outside of the swine flu pandemic in 2009. Most of them were unvaccinated. That's why some doctors are hoping that the first nasal flu vaccine available for use at home can improve vaccination rates among people, especially children, who are afraid of needles. AstraZeneca's FluMist Home, which was approved last fall, is now available with a prescription for children ages 2 and over, and adults up to age 49. A 2019 review from researchers at the University of Michigan found the majority of children and up to 30% of young adults are afraid of needles. Dr. Zachary Hoy, board-certified pediatric infectious disease specialist at Pediatrix Medical Group in Nashville, Tennessee, said many children are scared because they aren't old enough to understand what vaccines are and why they are important. 'Most of the time, the anxiety and worry before the shot is scarier than the actual shot,' Hoy said. How does FluMist Home work? The vaccine was first approved in 2003 to be given in a doctor's office. However, after the 2009 swine flu pandemic introduced the new H1N1 strain, several studies found the nasal spray was less effective than other flu vaccines. This prompted the Centers for Disease Control and Prevention to recommend against using the nasal spray in 2016. At the time, the CDC said the nasal spray accounted for one-third of all flu vaccines given to children. In response, FluMist's manufacturers reformulated it to more closely match circulating strains, including H1N1, and the nasal spray returned in 2018. Like injectable flu vaccines, FluMist is updated each season based on recommendations from global health officials. 'FluMist's efficacy is comparable to injectable flu vaccines and is a safe and effective needle-free option for flu protection,' AstraZeneca spokesperson Andrew Leone said. Experts say it's too early to tell how bad the upcoming flu season will be. Typically, flu vaccines are 40% and 60% effective in preventing severe illness, and FluMist Home should be equally protective. The doses for the 2026-2027 season contain three virus strains: an A/H1N1 strain, an A/H3N2 strain and a B strain from the B/Victoria lineage, according to the drugmaker. The FluMist Home vaccine contains a weakened form of a live virus to stimulate the immune system. Pregnant women or people with compromised immune systems are advised to talk with their doctor before using it. Does insurance cover it? FluMist Home is available only online. People ordering the nasal spray will need to complete a medical screening questionnaire at that is reviewed by a health care professional, according to the drugmaker. FluMist Home's online pharmacy will then collect the insurance information and bill the health plan directly. A temperature monitor on the packaging will verify that the vaccine has been maintained at the appropriate temperature during shipping and delivery. Green means it's safe to use. Red means it's not. Christina Aungst, senior pharmacy editor at GoodRx, estimates people with insurance will likely only have to pay an $8.99 shipping fee for the nasal spray. 'Currently, if you don't have insurance, FluMist is only available in a health care setting,' AstraZeneca's Leone said. 'We hope to provide a cash pay option for FluMist Home in future seasons.' When FluMist is given in a health care office or clinic, most insurance plans — including Medicare and Medicaid — will cover it. Dr. Scott Roberts, associate medical director of infection prevention at Yale School of Medicine, worries people may not administer the nasal spray vaccine properly without a doctor's supervision. 'What if they have a runny nose? How far back do they need to spray in the nose? What if they store it incorrectly in their house?' Roberts asked. Dr. Kristina Bryant, pediatric infectious diseases physician at Norton Children's in Louisville, Kentucky, and a member of the American Academy of Pediatrics Committee on Infectious Diseases, said the bottom line is that all the available flu vaccines offer comparable protection. 'The most important thing to know is that vaccines only work if they are actually administered,' Bryant said. 'Hopefully, the availability of a vaccine that can be administered in the home will make it easier for some people to be protected against flu.'
Time Magazine
4 days ago
- Time Magazine
Cutting mRNA Research Could Be Our Deadliest Mistake Yet
The U.S. Department of Health and Human Services (HHS) recently announced it will wind down funding for mRNA vaccine development—which could prove to be one of the costliest, deadliest decisions HHS Secretary Robert F. Kennedy Jr. will make during his tenure. HHS has already scaled back access to and recommendations for COVID-19 vaccines—a decision experts are deeply concerned about—and Kennedy's frequently misinformed views on vaccines continue to fan the flames of anti-vaccination attitudes. Now, Kennedy's failure to fully explore the potential of mRNA vaccines could stagnate research that has the potential to save millions of lives around the world. The dark cloud of COVID-19, one of the deadliest infectious disease outbreaks in history, can hardly be thought of as having a silver lining. But the nearest thing to a glimmer of a positive would be that the fast development of COVID-19 vaccines helped prevent many more deaths and led to rapid progress in our understanding and use of mRNA technology. This greater understanding is now being explored as potential preventions or therapies for a wide range of diseases, from H5N1 bird flu and HIV to cancer. Terminating 22 mRNA projects will not only directly set back research on mRNA vaccines for infectious diseases including flu; it will also arguably have negative knock-on effects for researchers the world over exploring personalized treatments for noncommunicable diseases like cancer. Early research on some novel uses of mRNA is promising. For example, a preliminary trial of an mRNA HIV vaccine found that 80% of participants generated neutralizing antibodies, which in theory could help block HIV—pending further research and development. A melanoma mRNA vaccine, when combined with existing treatment, reduced the risk of death or disease recurrence by nearly 50%. (The vaccine is currently being tested further in a full scale Phase 3 clinical trial). Even more amazingly, personalized vaccines—where vaccines are created specifically for an individual using information from their cancer to optimize their immune response—using mRNA technology have even been proposed as a universal vaccine adaptable for all cancers. Read More: The CDC Shooting is a Dark Sign for Science and America Much of the research on personalized mRNA cancer vaccines is in some way indebted to gains in knowledge made from COVID-19 research, and it stands to reason that pulling such a large amount of funding from mRNA projects will slow down further progress in these areas. Approximately $500 million worth of research funding would almost certainly have advanced the scientific community's fundamental understanding of how, and to what extent, mRNA technology works and how it could be applied to prevent and fight disease. Also problematic is the manner in which HHS under Kennedy conveys their decisions. In announcing the funding withdrawal, HHS states it 'will focus on platforms with stronger safety records and transparent clinical and manufacturing data practices.' This implies that mRNA vaccines have not been properly or transparently tested—which is not true. The safety of COVID-19 mRNA vaccines has been demonstrated in numerous studies and systematic evidence reviews. Like pretty much all vaccines and treatments, mRNA vaccines are not without side effects, but evidence shows that any adverse events are nearly always mild and short-lived. COVID-19 vaccines have already saved millions of lives globally, with mRNA vaccines accounting for a significant majority of all doses administered in many countries. Kennedy's claim that 'mRNA technology poses more risk than benefits' is almost farcical in light of scientific evidence. Moreover, the whole purpose of clinical research is to test whether new scientific innovations—like novel applications of mRNA into different diseases—are safe and effective in the first place. Kennedy has long spoken of how we need more evidence and testing on mRNA vaccines, and so it is painfully ironic that he is pulling funding for research which would enable the scientific community to do just that. Read More: An mRNA Melanoma Vaccine Shows Promise Perhaps most concerning is the caliber of evidence upon which decisions with such massive implications are being made. In an HHS announcement of the termination of mRNA projects, Kennedy claims 'the data show these vaccines fail to protect effectively against upper respiratory infections like COVID and flu.' The truth is, initial vaccines and booster doses have been shown to be very effective against reducing infection, hospitalization, and death from COVID-19. Kennedy does not even provide links or citations to systematic reviews or meta-analyses in reputable journals, the gold standard methods for scientific evidence. Rather, he simply links to an online evidence review which cherry picks studies searching only for the harms—and not the overall safety, effectiveness, or cost-benefit analysis—of the mRNA vaccines. The report does not describe the methods used to select and review studies, nor does it appear itself to have been peer-reviewed by other scientists. It almost certainly wouldn't be publishable in a scientific journal, yet it is being used as evidence to justify the fate of half a billion dollars of research funds. This is another example of how fringe viewpoints on mRNA technology, instead of the best available scientific evidence, are under Kennedy and HHS becoming the new mainstream. The U.S. has been at the forefront of developing mRNA technology for the past few decades, from the Nobel Prize-winning research of professors Katalin Kariko and Drew Weissman at the University of Pennsylvania on mRNA, to the key role of U.S.-based pharmaceutical companies in vaccine production and rollout. Perhaps other countries, companies, and funding sources will offset this funding loss and lead the development of mRNA vaccine innovations. Large investments are already being made in the U.K. and China, for example. That would be to the detriment of U.S. scientific innovation and progress. Kennedy is right to scrutinize the potential overreach of the pharmaceutical industry, and to ensure their research and development is ethical and transparent. However, his seemingly personal war against "Big Pharma" and ideological opposition to mRNA risks stunting research that could one day help prevent the next pandemic or even provide cures for hitherto incurable cancers.
4 days ago
AstraZeneca launches at-home FluMist nasal spray delivery
AstraZeneca is making flu protection more convenient with the launch of an at-home delivery option for FluMist, its nasal spray flu vaccine, the company announced Friday. On the market since 2003, FluMist was previously only available at pharmacies or doctors' offices. Beginning Friday, eligible customers can order it online and have it shipped directly to their door, allowing parents to vaccinate their children at home without shots or a trip to the pharmacy. The spray can be self-administered by adults up to age 49, while caregivers can give it to children ages 2–17, the company said. The FDA approved FluMist for self- and caregiver-administration in September 2024, after research showed adults over 18 could safely and effectively administer it to eligible individuals. AstraZeneca hopes the needle-free option and at-home convenience will boost vaccination rates this year. Last year's flu season saw the highest number of flu-related deaths for children for a non-pandemic year -- 267 -- since the 2009 H1N1 pandemic, according to the Centers for Disease Control and Prevention. Health experts stress that vaccination remains the best protection against the virus, though getting kids vaccinated can be a challenge. The CDC continues to recommend that everyone 6 months and older get a flu vaccine this fall. Most health insurance plans are expected to cover the cost, with a shipping fee for four FluMist doses estimated at under $10. The company added for those who qualify, the nasal spray offers safety and effectiveness comparable to traditional flu shots.
